极低体重老年患者按体重给予依诺肝素用于静脉血栓栓塞预防
本病例报告描述一名68岁女性、体重仅21.8 kg的极低体重患者,因肺炎和慢阻肺急性加重入院,Padua评分5分、IMPROVE评分2分,需药物性VTE预防。临床采用按体重0.5 mg/kg(10 mg)皮下每日一次依诺肝素,并使用儿科稀释液给药,通过抗Xa峰值监测确认预防水平达标。
要点
- 极低体重患者VTE预防缺乏循证剂量,本病例采用0.5 mg/kg依诺肝素每日一次。
- 使用儿科稀释液实现低剂量精准给药,并以抗Xa峰值0.21 units/mL确认预防达标。
- 体重<40 kg成人VTE预防的最佳抗凝剂量证据有限,需个体化并考虑监测。
核心结论
- 本病例报道了极低体重老年患者使用按体重依诺肝素策略进行VTE预防,并达到治疗性预防抗Xa水平。
研究设计与样本
- 单例病例报告:68岁女性,体重21.8 kg,因肺炎和慢阻肺急性加重入院。
主要发现
- 患者Padua评分5分、IMPROVE评分2分,提示需要药物性VTE预防。
- 依诺肝素0.5 mg/kg(10 mg)皮下每日一次,使用儿科稀释液给药。
- 抗Xa峰值为0.21 units/mL,被认为达到合适的VTE预防水平。
关键数值与推荐
- 依诺肝素剂量为0.5 mg/kg(10 mg)皮下每日一次。
- 抗Xa峰值0.21 units/mL被视为合适的预防水平。
- 文献回顾显示体重<40 kg成人VTE预防的最佳抗凝剂量证据很少。
临床怎么用
- 对极低体重患者可考虑按体重计算依诺肝素预防剂量,并使用稀释液实现精准给药。
- 可考虑监测抗Xa峰值以确认预防剂量是否达标。
局限性
- 单例病例报告,不能推广至所有极低体重患者。
- 文献缺乏体重<40 kg成人VTE预防的最佳抗凝剂量证据。
- 尚无针对极端低体重患者达到治疗范围抗Xa水平的可用证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this report is to highlight a case of utilizing weight-based enoxaparin for prophylaxis of venous thromboembolism (VTE) in an elderly, extremely underweight patient. VTE represents a significant concern for hospitalized patients. There is a dearth of literature regarding utilization of low-molecular-weight heparins such as enoxaparin or unfractionated heparin in patients who are underweight. SUMMARY: In this case, a 68-year-old female who was extremely underweight (21.8 kg) presented to the emergency department in acute respiratory distress secondary to pneumonia and a chronic obstructive pulmonary disease exacerbation. The patient had a Padua score of 5 and an IMPROVE score of 2 that signified the necessity of pharmacologic VTE prophylaxis. A clinical decision was made to utilize a weight-based enoxaparin dosing strategy for VTE prophylaxis using a pediatric dilution to deliver the dose. Enoxaparin was initiated at 0.5 mg/kg (10 mg) subcutaneously daily and monitored via anti-factor Xa peak levels to verify that the dose provided an adequate prophylactic level. Ultimately, a dose of 0.5 mg/kg resulted in an appropriate anti-factor Xa level of 0.21 units/mL, equating to suitable VTE prophylaxis. CONCLUSION: A review of the literature revealed little evidence for optimal anticoagulation dosing for VTE prophylaxis in adult patients weighing under 40 kg. Various adjustment strategies have been utilized; however, there is no available evidence pertaining to patients at the extreme of low weight represented by the reported case or to attainment of an anti-factor Xa level within the therapeutic range in such patients. This case represents the use of a weight-based enoxaparin strategy for an extremely underweight elderly patient and the attainment of a therapeutic prophylactic anti-factor Xa level.
引用
- Lanier C, Lassiter M, Covert K, et al. Use of weight-based dosing of enoxaparin for venous thromboembolism prophylaxis in an extremely underweight elderly patient. Am J Health Syst Pharm. 2026. PMID: 41807259. doi:10.1093/ajhp/zxag080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。